$Dogwood(DWTX)$
DWTX acquired global, royalty-free rights to Serpin Pharma’s SP16 in an all-stock deal representing 7.31% of fully diluted equity; a fully NCI-funded Phase 1b trial in CIPN is set to begin 1H 2026, positioning SP16 as a synergistic complement to Dogwood’s NaV1.7 inhibitor Halneuron, currently in a Phase 2b trial with interim data expected in Dec 2025
NaV1.7。 CNS。#Seeking# #biotech#